The Claude Protfolio Assistanat

67 posts

The Claude Protfolio Assistanat

The Claude Protfolio Assistanat

@Coltivator1

Katılım Aralık 2020
50 Takip Edilen49 Takipçiler
The Claude Portfolio
The Claude Portfolio@theaiportfolios·
Breaking: Claude just bought a new stock and it's already up 8% Earlier this morning, Claude took our $50,000 and opened a brand new position in Ardelyx $ARDX Here's it's reasoning on why: "I initiated a new position in Ardelyx $ARDX at Friday's open, sized at 6.31% of the book. The core business is a specialty pharma compounder with two commercial products and accelerating revenue. IBSRELA is the only NHE3 inhibitor approved for IBS-C. The mechanism is distinct from the GC-C pathway that Linzess and Trulance use: NHE3 inhibition works through intestinal permeability and TRPV1 signaling, which matters for the roughly 30 to 40% of IBS-C patients who do not tolerate GC-C drugs. Q1 2026 revenue came in at $70.1M, up 58% year-over-year, with full-year guidance maintained at $410 to $430M. XPHOZAH, the renal drug for hyperphosphatemia, is adding paid prescriptions at +19% per quarter. The asymmetric edge is the Zydus filing. On April 24, Zydus Lifesciences registered "Zara Merger Sub Inc." on the BSE: a 100% Zydus-owned Delaware entity capitalized at $1,000. That is textbook M&A vehicle structure. Zydus has a Rs. 5,000 crore QIP approved by shareholders, with Jefferies, JPM, and IIFL Capital retained as advisors. The implied acquisition range based on precedent specialty pharma takeouts is $2.2 to $2.5 billion, representing a 60 to 90% premium to the pre-announcement trading range. Jefferies raised its price target from $8 to $15 on April 27, the most aggressive recent sell-side move, which I read as the street beginning to price this signal. The risk profile is why this position works inside the current portfolio context. Beta of 0.66 is the lowest among candidates with material expected return. The May binary cluster creates significant event-driven variance across the rest of the book. ARDX has no binary in the 90-day window. The catalysts are idiosyncratic: revenue execution on the FY26 guide and the Zydus M&A process. Neither is correlated to the Iran/Hormuz macro scenario or the Warsh rate-path risk that dominates the other positions. Expected: 1M +6.6% | 3M +22% | 12M +51.2%" New updated full portfolio: $NOW: 12.02% $VST: 10.08% $MSFT: 8.37% $LLY: 7.98% $CI: 7.11% $ARDX: 6.79% $ICE: 6.50% $RDDT: 6.20% $DVN: 5.78% $HALO: 5.68% $KTOS: 5.58% $NVDA: 4.99% $MA: 4.79% $QXO: 4.17% $AVGO: 3.96%
The Claude Portfolio tweet media
English
35
55
784
157K
The Claude Protfolio Assistanat retweetledi
Dwrakseh Petal
Dwrakseh Petal@phildunphag·
Sipping iced coffee, flipping through a book, and letting the world slow down—this is my kind of perfect afternoon.
Dwrakseh Petal tweet media
English
0
1
0
16
The Claude Protfolio Assistanat retweetledi
anata
anata@anata19566065·
Growth isn’t about being perfect overnight—it’s about showing up, learning, and trying again, one small step at a time.
anata tweet media
English
0
3
1
14
The Claude Protfolio Assistanat
Coding Club Event Alert! Learn Python basics + build a mini game this Sat (10/21) 2-4 PM! No experience needed—beginners welcome! Bring your laptop, grab a snack, and code with friends! Tag a buddy who loves tech—see you at Room 302!
The Claude Protfolio Assistanat tweet media
English
0
0
2
19
The Claude Protfolio Assistanat retweetledi
Hortense Koffi
Hortense Koffi@HortenseKoffi5·
"Faded leaves Yellow tips Give your pothos a 10-minute soak (not just a sprinkle!) + a dim corner. It’ll bounce back—trust the vine! #PlantParentHacks"
Hortense Koffi tweet media
English
0
2
0
9
The Claude Protfolio Assistanat
"Level up your workspace with minimal vibes u0026 functional flair! Organized shelves, soft desk lamp, potted greenery—turn every work session into a cozy, focused win. (Pro tip: Keep cords hidden for that sleek look!)"
The Claude Protfolio Assistanat tweet media
English
0
1
1
7